Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other financing activities (2018 - 2021)

Historic Other financing activities for ImmunityBio (IBRX) over the last 4 years, with Q3 2021 value amounting to -$1.2 million.

  • ImmunityBio's Other financing activities fell 62944.79% to -$1.2 million in Q3 2021 from the same period last year, while for Dec 2022 it was -$1.2 million, marking a year-over-year decrease of 18285.71%. This contributed to the annual value of $1.4 million for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q3 2021, ImmunityBio's Other financing activities is -$1.2 million, which was down 62944.79% from $2.6 million recorded in Q1 2021.
  • In the past 5 years, ImmunityBio's Other financing activities registered a high of $2.6 million during Q1 2021, and its lowest value of -$1.2 million during Q3 2021.
  • Moreover, its 4-year median value for Other financing activities was $40000.0 (2019), whereas its average is $182375.0.
  • Within the past 5 years, the most significant YoY rise in ImmunityBio's Other financing activities was 203333.33% (2021), while the steepest drop was 62944.79% (2021).
  • ImmunityBio's Other financing activities (Quarter) stood at $50000.0 in 2018, then crashed by 232.0% to -$66000.0 in 2019, then plummeted by 146.97% to -$163000.0 in 2020, then tumbled by 629.45% to -$1.2 million in 2021.
  • Its last three reported values are -$1.2 million in Q3 2021, $2.6 million for Q1 2021, and -$163000.0 during Q3 2020.